{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:25:23Z","timestamp":1793715923025,"version":"4.6.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010052","name":"Northumbria University","doi-asserted-by":"publisher","award":["APR9\\1024"],"award-info":[{"award-number":["APR9\\1024"]}],"id":[{"id":"10.13039\/100010052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide and a major risk factor for hepatocellular carcinoma (HCC). Its rising prevalence and progression to HCC present major clinical and public health challenges. Current diagnostic and prognostic tools lack accuracy in predicting disease progression and early HCC risk. Emerging approaches, including artificial intelligence (AI), machine learning (ML), and polygenic risk scores (PRS) offer promising opportunities and improvements in non-invasive diagnosis, risk stratification, and precision medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a scoping review synthesising evidence on the application of PRS and AI\/ML models for predicting and detecting MASLD, assessing fibrosis, and stratifying risk of HCC among individuals with MASLD\/NAFLD, with a particular focus on European and Asian populations. The review was performed in accordance with PRISMA 2020 guidelines and aimed to map the development trajectory and knowledge structure of predictive approaches for MASLD\/NAFLD\u2013HCC risk stratification, while identifying key translational challenges and opportunities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evidence from the included studies indicates a shift from isolated methodological innovation towards integrated, explainable, and clinically validated multimodal models, supported by transparent AI\/ML systems aligned with regulatory frameworks. There is also a critical need for large, multi-centre validation studies and interdisciplinary collaboration among clinicians, data scientists, and policymakers to enable scalable and equitable implementation. Furthermore, progress depends on moving from theoretical promise to clinical reality through prospective trials that assess real-world effectiveness and adoption pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review highlights advances in AI and PRS for HCC risk prediction in MASLD\/NAFLD, demonstrating that multimodal models outperform traditional approaches. AI-driven methods show strong potential for MASLD detection, fibrosis assessment, and HCC risk stratification, with implications for improved clinical outcomes. However, translation into practice is limited by poor genetic integration, lack of validation, population bias, and limited explainability. Further validation, standardization, and clinical integration are required for widespread adoption and effective personalised surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1803957","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:57:37Z","timestamp":1782889057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review"],"prefix":"10.3389","volume":"16","author":[{"given":"Anvitha","family":"Nagaraj Sharma","sequence":"first","affiliation":[{"name":"Bioinformatic & Multi-Omics Data Science Group, Faculty of Sciences and Environment, Northumbria University","place":["Newcastle, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hima","family":"Bhagavatula","sequence":"additional","affiliation":[{"name":"Bioinformatic & Multi-Omics Data Science Group, Faculty of Sciences and Environment, Northumbria University","place":["Newcastle, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Mapundu","sequence":"additional","affiliation":[{"name":"Bioinformatic & Multi-Omics Data Science Group, Faculty of Sciences and Environment, Northumbria University","place":["Newcastle, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile R.","family":"Chimusa","sequence":"additional","affiliation":[{"name":"Bioinformatic & Multi-Omics Data Science Group, Faculty of Sciences and Environment, Northumbria University","place":["Newcastle, United Kingdom"]},{"name":"AI and Data-Driven Department, Omics Data Solutions Limited","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2024.103","article-title":"No more NAFLD: The term is now MASLD","volume":"39","author":"Bae","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000282080","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-013-9480-x","article-title":"Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)","volume":"7","author":"Duseja","year":"2013","journal-title":"Hepatol Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040614","article-title":"The link between NAFLD and metabolic syndrome","volume":"13","author":"Radu","year":"2023","journal-title":"Diagnostics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD single topic conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicentre prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s272213","article-title":"NAFLD-associated HCC: progress and opportunities","volume":"8","author":"Geh","year":"2021","journal-title":"J Hepatocellular Carcinoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.53590\/japt.02.1030","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: insights in epidemiology, pathogenesis, imaging, prevention and therapy","volume":"93","author":"Polyzos","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.944088","article-title":"The pathogenesis of HCC driven by NASH and the preventive and therapeutic effects of natural products","volume":"13","author":"Shao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i28.3595","article-title":"Non-alcoholic fatty liver disease-related hepatocellular carcinoma: is there a role for immunotherapy","volume":"28","author":"Mattos \u00c2","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.014","article-title":"The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications","volume":"72","author":"Hou","year":"2020","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100811","article-title":"Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma","volume":"5","author":"Talamantes","year":"2023","journal-title":"JHEP Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.06.120","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40001-024-01708-8","article-title":"Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches","volume":"29","author":"Mahmoudi","year":"2024","journal-title":"Eur J Med Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.048","article-title":"HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"Krawczyk","year":"2015","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: A novel genetic player in nonalcoholic fatty liver\u00a0and cardiovascular disease","volume":"6","author":"Luo","year":"2022","journal-title":"Hepatol Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20868","article-title":"The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6661858","article-title":"Prevalence of GCKR rs1260326 variant in subjects with obesity associated NAFLD and T2DM: a case-control study in South Punjab, Pakistan","volume":"2023","author":"Nisar","year":"2023","journal-title":"J Obes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.3390\/jcm10204638","article-title":"Prevalence of the absence of cirrhosis in subjects with NAFLD-associated hepatocellular carcinoma","volume":"10","author":"Castellana","year":"2021","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1567870","article-title":"Insights from genome-wide association analyses of nonalcoholic fatty liver disease","volume":"35","author":"Kahali","year":"2015","journal-title":"Semin Liver Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/460190","article-title":"Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis","volume":"2015","author":"Dongiovanni","year":"2015","journal-title":"BioMed Res Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.818574","article-title":"Calculating polygenic risk scores (PRS) in UK Biobank: A practical guide for epidemiologists","volume":"13","author":"Collister","year":"2022","journal-title":"Front Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-21448-6_2","article-title":"Artificial intelligence: definition and background","volume-title":"Mission Ai: The New System Technology","author":"Sheikh","year":"2023"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12525-021-00475-2","article-title":"Machine learning and deep learning","volume":"31","author":"Janiesch","year":"2021","journal-title":"Electronic Markets"},{"key":"B49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s40001-025-02680-7","article-title":"Unveiling the potential of artificial intelligence in revolutionizing disease diagnosis and prediction: a comprehensive review of machine learning and deep\u00a0learning approaches","volume":"30","author":"Sadr","year":"2025","journal-title":"Eur J Med Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12967-025-06425-2","article-title":"Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpbup.2024.100146","article-title":"AI in diagnostic imaging: Revolutionising accuracy and efficiency","volume":"5","author":"Khalifa","year":"2024","journal-title":"Comput Methods Programs Biomedicine Update"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/jgh.16663","article-title":"Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature","volume":"39","author":"Chatzipanagiotou","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00680","article-title":"Deep learning for accurate diagnosis of liver tumor based on magnetic resonance imaging and clinical data","volume":"10","author":"Zhen","year":"2020","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106706","article-title":"Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases","volume":"189","author":"Bakrania","year":"2023","journal-title":"Pharmacol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107352","article-title":"Liver investigation: testing marker utility in steatohepatitis (LITMUS): assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): study protocol","volume":"134","author":"Pavlides","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqaf038","article-title":"AI-powered precision medicine: utilizing genetic risk factor optimization to revolutionize healthcare","volume":"7","author":"Alsaedi","year":"2025","journal-title":"NAR Genom Bioinform"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501394785250715165404","article-title":"Role of artificial intelligence in nanomedicine and organ-specific therapy: an updated review","volume":"26","author":"Rajpoot","year":"2025","journal-title":"Curr Drug Targets"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211062807","article-title":"Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis","volume":"14","author":"Decharatanachart","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100002","article-title":"Application of artificial intelligence in the diagnosis of hepatocellular carcinoma","volume":"1","author":"Benjamin","year":"2023","journal-title":"eGastroenterology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1591523","article-title":"Artificial intelligence in imaging for liver disease diagnosis","volume":"12","author":"Yin","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2023.107932","article-title":"Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: a systematic review, (2005\u20132023)","volume":"244","author":"Zamanian","year":"2024","journal-title":"Comput Methods Programs BioMed"},{"key":"B63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21037\/tgh-24-41","article-title":"Hepatocellular carcinoma risk prediction and early detection in patients with metabolic dysfunction associated steatotic liver disease","volume":"9","author":"Liang","year":"2024","journal-title":"Trans Gastroenterol Hepatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2021.0604","article-title":"Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis","volume":"34","author":"Cholongitas","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003149","article-title":"Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts","volume":"17","author":"Atabaki-Pasdar","year":"2020","journal-title":"PloS Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101528","article-title":"Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records","volume":"29","author":"Drozdov","year":"2024","journal-title":"Ann Hepatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41598-023-30750-5","article-title":"Machine learning classifiers for screening nonalcoholic fatty liver disease in general adults","volume":"13","author":"Qin","year":"2023","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e2413835","DOI":"10.1002\/advs.202413835","article-title":"Development and validation of machine learning-based marker for early detection and prognosis stratification of nonalcoholic fatty liver disease","volume":"12","author":"Xiao","year":"2025","journal-title":"Adv Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.gastha.2024.06.007","article-title":"Use of machine learning to predict onset of NAFLD in an all-comers cohort \u2014 development and validation in 2 large Asian cohorts","volume":"3","author":"Lim","year":"2024","journal-title":"Gastro Hep Advances"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.105837","article-title":"FibrAIm - The machine learning approach to identify the early stage of liver fibrosis and steatosis","volume":"197","author":"Ginter-Matuszewska","year":"2025","journal-title":"Int J Med Inform"},{"key":"B73","doi-asserted-by":"publisher","first-page":"103661","DOI":"10.1016\/j.ebiom.2021.103661","article-title":"The altered serum lipidome and its diagnostic potential for non-alcoholic fatty liver (NAFL)-associated hepatocellular carcinoma","volume":"73","author":"Lewinska","year":"2021","journal-title":"Ebiomedicine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15710","article-title":"Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome","volume":"51","author":"Moolla","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.3390\/ijms23168841","article-title":"Discovering biomarkers for non-alcoholic steatohepatitis patients with and without hepatocellular carcinoma using fecal metaproteomics","volume":"23","author":"Sydor","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B76","unstructured":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality If non-Randomized Studies in Meta-Analyses\n          \n          \n            \n              Wells\n              GA\n            \n            \n              Shea\n              B\n            \n            \n              O\u2019Connell\n              D\n            \n            \n              Peterson\n              J\n            \n            \n              Welch\n              V\n            \n            \n              Losos\n              M\n            \n          \n          \n          2000"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s11633-024-1506-4","article-title":"Multimodal learning-based prediction for nonalcoholic fatty liver disease","volume":"22","author":"Chen","year":"2025","journal-title":"Mach Intell Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1303426","article-title":"Machine learning identifies\u00a0ferroptosis-related gene ANXA2 as potential diagnostic biomarkers for NAFLD","volume":"14","author":"Qin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12880-024-01398-y","article-title":"Machine learning model for non-alcoholic steatohepatitis diagnosis based on ultrasound radiomics","volume":"24","author":"Xia","year":"2024","journal-title":"BMC Med Imaging"},{"key":"B81","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s12967-024-05315-3","article-title":"A novel effective and safe model for the diagnosis of nonalcoholic fatty liver disease in China: gene excavations, clinical validations, and mechanism elucidation","volume":"22","author":"Wang","year":"2024","journal-title":"Journal of Translational Medicine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1631265","article-title":"Using machine learning methods to investigate the role of volatile organic compounds in non-alcoholic fatty liver disease","volume":"12","author":"Shen","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"036011","DOI":"10.1088\/1752-7163\/addff9","article-title":"The machine learning prediction model of non-alcoholic fatty liver; the role of hydrogen and methane breath tests","volume":"19","author":"An","year":"2025","journal-title":"J Breath Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/apt.17891","article-title":"Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease \u2013 The Gut and Obesity in Asia (GO-ASIA) Study","volume":"59","author":"Verma","year":"2024","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/MEG.0000000000002641","article-title":"Multicenter validation of FIB-6 as a novel machine learning non-invasive score to rule out liver cirrhosis in biopsy-proven MAFLD","volume":"35","author":"Anushiravani","year":"2023","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.gastha.2024.01.007","article-title":"A machine learning model to predict risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"3","author":"Sarkar","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1450317","article-title":"Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation","volume":"15","author":"Yang","year":"2024","journal-title":"Frontiers in Endocrinology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"152909","DOI":"10.1016\/j.imbio.2025.152909","article-title":"Interpretable machine learning reveals the role of PANoptosis in the diagnosis and subtyping of NAFLD","volume":"230","author":"Tian","year":"2025","journal-title":"Immunobiology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1109\/ACCESS.2025.3568918","article-title":"Enhancing liver cirrhosis diagnosis using machine learning with explainable AI and cross-validated hyperparameter tuning techniques","volume":"13","author":"Makkena","year":"2025","journal-title":"IEEE Access"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.1038\/s41598-025-96478-6","article-title":"Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods","volume":"15","author":"Yu","year":"2025","journal-title":"Sci Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"B92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1381\/0960892053723268","article-title":"Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies","volume":"15","author":"Janiec","year":"2005","journal-title":"Obes Surg"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16602","article-title":"Practices of liver biopsy in France: Results of a prospective nationwide survey","volume":"32","author":"Cadranel","year":"2000","journal-title":"Hepatology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejm200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s42256-021-00307-0","article-title":"Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans","volume":"3","author":"Roberts","year":"2021","journal-title":"Nat Mach Intell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109569","article-title":"Local interpretable model-agnostic explanation approach for medical imaging analysis: A systematic literature review","volume":"185","author":"Hassan","year":"2025","journal-title":"Comput Biol Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0304-0","article-title":"Explainable machine-learning predictions for the prevention of hypoxaemia during surgery","volume":"2","author":"Lundberg","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"B99","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41746-020-00323-1","article-title":"The future of digital health with federated learning","volume":"3","author":"Rieke","year":"2020","journal-title":"NPJ Digit Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2525006","article-title":"Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy","volume":"28","author":"Maas","year":"2025","journal-title":"J Med Econ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:57:45Z","timestamp":1782889065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":100,"alternative-id":["10.3389\/fonc.2026.1803957"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1803957","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1803957"}}